Researching Cardiovascular Events with a Weekly Incretin in Diabetes

What is REWIND?

The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) study aims to see whether the investigational drug, dulaglutide, can safely reduce the development of serious heart disease or stroke in people with type 2 diabetes who are at high risk for these conditions.

This study is currently following participants.